Whether it’s vaccines, children’s health or impact investing mechanisms, partnerships are absolutely critical nowadays to maximizing success and development impact.
At an event hosted Friday by Devex Impact at Pfizer’s New York headquarters, the conversation ranged from vaccine distribution and Ebola to impact investing layer cakes and the need for more knowledge sharing.
“We like to look at our contribution as beyond the vaccine,” said Susan Silbermann, Pfizer Vaccines president and general manager. “The more we can sit at the table as a whole partner and not just as the guy that makes the stuff … the more these public-private partnerships will flourish.”
Pfizer, she explained, is working to bring its expertise, as well as its ability to generate and review evidence and scientific knowledge to tackle key health issues around the world.
In their case, one of the main challenges is investing in the infrastructure for prevention, and part of that means figuring out how to design vaccines to reduce waste, storage space and the need for cold so they can get to that last mile distribution. Pfizer is currently awaiting review of a new vaccine that would have a three-day shelf life in temperatures above 40 degrees Celsius.